$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000106282221000063 Filed on November 09, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$14.00K	$23.00K	$6.634M
YoY Change	-93.0%	-99.65%	-97.75%
Cost Of Revenue	$0.00	$0.00	$633.0K
YoY Change		-100.0%	9.71%
Gross Profit	$14.00K	$23.00K	$6.001M
YoY Change	-93.0%	-99.62%	-97.96%
Gross Profit Margin	100.0%	100.0%	90.46%
Selling, General & Admin	$8.846M	$7.303M	$12.00M
YoY Change	38.22%	-39.14%	-13.67%
% of Gross Profit	63185.71%	31752.17%	199.97%
Research & Development	$16.50M	$15.68M	$40.15M
YoY Change	1549.8%	-60.94%	50.59%
% of Gross Profit	117842.86%	68182.61%	669.01%
Depreciation & Amortization	$112.0K	$101.0K	$800.0K
YoY Change	-62.67%	-87.38%	-11.11%
% of Gross Profit	800.0%	439.13%	13.33%
Operating Expenses	$25.34M	$22.99M	$52.78M
YoY Change	242.49%	-56.45%	-24.36%
Operating Profit	-$25.33M	-$22.96M	$86.68M
YoY Change	251.81%	-126.49%	-61.42%
Interest Expense	-$295.0K	$171.0K	$4.118M
YoY Change	47.5%	-95.85%	-20.87%
% of Operating Profit			4.75%
Other Income/Expense, Net	$14.00K	$11.00K	$301.0K
YoY Change	-98.44%	-96.35%	-49.83%
Pretax Income	-$25.61M	-$23.12M	$82.60M
YoY Change	365.65%	-127.99%	-62.47%
Income Tax			$0.00
% Of Pretax Income			0.0%
Net Earnings	-$25.61M	-$23.12M	$82.60M
YoY Change	365.65%	-127.99%	-63.46%
Net Earnings / Revenue	-182935.71%	-100530.43%	1245.15%
Basic Earnings Per Share		-$0.16	$0.77
Diluted Earnings Per Share	-$172.0K	-$0.16	$0.71
COMMON SHARES
Basic Shares Outstanding	148.9M shares	145.8M shares	107.3M shares
Diluted Shares Outstanding		145.8M shares	117.6M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$86.74M	$120.9M	$111.4M
YoY Change	-43.04%	8.54%	-62.4%
Cash & Equivalents	$64.07M	$92.12M	$52.25M
Short-Term Investments	$22.68M	$28.80M	$59.20M
Other Short-Term Assets	$2.164M	$3.064M	$9.109M
YoY Change	-57.14%	-66.36%	52.5%
Inventory			$0.00
Prepaid Expenses
Receivables	$14.00K	$23.00K	$1.383M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$88.92M	$124.0M	$121.9M
YoY Change	-43.62%	1.7%	-66.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.176M	$1.311M	$11.11M
YoY Change	298.64%	-88.2%	-23.62%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles			$0.00
YoY Change			-100.0%
Long-Term Investments
YoY Change
Other Assets	$2.269M	$2.471M	$1.341M
YoY Change	84.32%	84.27%	-23.55%
Total Long-Term Assets	$47.99M	$48.33M	$56.99M
YoY Change	4.17%	-15.2%	-29.64%
TOTAL ASSETS
Total Short-Term Assets	$88.92M	$124.0M	$121.9M
Total Long-Term Assets	$47.99M	$48.33M	$56.99M
Total Assets	$136.9M	$172.3M	$178.9M
YoY Change	-32.82%	-3.69%	-59.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.152M	$8.345M	$11.73M
YoY Change	67.34%	-28.88%	-43.88%
Accrued Expenses	$12.97M	$14.21M	$58.50M
YoY Change	-56.31%	-75.71%	408.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$11.69M	$8.691M
YoY Change	-100.0%	34.54%	-23.01%
Total Short-Term Liabilities	$22.12M	$34.25M	$78.92M
YoY Change	-52.73%	-56.61%	76.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$11.63M
YoY Change		-100.0%	-95.03%
Other Long-Term Liabilities	$1.190M	$1.481M	$738.0K
YoY Change	94.76%	100.68%	-39.26%
Total Long-Term Liabilities	$1.190M	$1.481M	$12.37M
YoY Change	94.76%	-88.02%	-94.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.12M	$34.25M	$78.92M
Total Long-Term Liabilities	$1.190M	$1.481M	$12.37M
Total Liabilities	$23.31M	$35.73M	$91.29M
YoY Change	-50.83%	-60.86%	-67.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.488B	-$1.462B	-$1.395B
YoY Change	6.27%	4.85%	8.08%
Common Stock	$150.0K	$150.0K	$117.0K
YoY Change	5.63%	28.21%	10.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$7.518M	$7.518M	$4.843M
YoY Change	55.23%	55.23%	26.88%
Treasury Stock Shares	1.165M shares	1.165M shares	793.0K shares
Shareholders Equity	$113.6M	$136.6M	$87.64M
YoY Change
Total Liabilities & Shareholders Equity	$136.9M	$172.3M	$178.9M
YoY Change	-32.82%	-3.69%	-59.75%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$25.61M	-$23.12M	$82.60M
YoY Change	365.65%	-127.99%	-63.46%
Depreciation, Depletion And Amortization	$112.0K	$101.0K	$800.0K
YoY Change	-62.67%	-87.38%	-11.11%
Cash From Operating Activities	-$22.83M	-$17.15M	-$40.30M
YoY Change	-33.45%	-57.44%	-121.13%
INVESTING ACTIVITIES
Capital Expenditures	-$23.00K	-$213.0K	$0.00
YoY Change	-77.0%
Acquisitions
YoY Change
Other Investing Activities	$6.119M	-$187.0K	$215.8M
YoY Change	-86.12%	-100.09%	-789.46%
Cash From Investing Activities	$6.096M	-$400.0K	$215.8M
YoY Change	-86.18%	-100.19%	-789.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-11.32M	19.78M	-210.1M
YoY Change	-117.63%	-109.42%	69933.33%
NET CHANGE
Cash From Operating Activities	-22.83M	-17.15M	-40.30M
Cash From Investing Activities	6.096M	-400.0K	215.8M
Cash From Financing Activities	-11.32M	19.78M	-210.1M
Net Change In Cash	-28.05M	2.231M	-34.60M
YoY Change	-137.91%	-106.45%	-121.75%
FREE CASH FLOW
Cash From Operating Activities	-$22.83M	-$17.15M	-$40.30M
Capital Expenditures	-$23.00K	-$213.0K	$0.00
Free Cash Flow	-$22.81M	-$16.94M	-$40.30M
YoY Change	-33.32%	-57.97%	-121.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Local Phone Number LocalPhoneNumber	863-3000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-30111
	dei	Entity Registrant Name EntityRegistrantName	Lexicon Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0474169
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2445 Technology Forest Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	11th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	The Woodlands
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77381
	dei	City Area Code CityAreaCode	281
	dei	Trading Symbol TradingSymbol	LXRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	148895707	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92118000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126263000	USD
CY2021Q3	us-gaap	Short Term Investments ShortTermInvestments	28800000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	26012000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	395000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	3064000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5049000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	124005000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	157719000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4849000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5815000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1311000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	295000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	44543000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2471000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1231000	USD
CY2021Q3	us-gaap	Assets Assets	172330000	USD
CY2020Q4	us-gaap	Assets Assets	203788000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	8345000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5469000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14208000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29691000	USD
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	11693000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	11646000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	34246000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46806000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1481000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	611000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	35727000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	47417000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	149987000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142289000	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	150000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	142000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1606142000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1561096000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1462165000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1400018000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6000	USD
CY2021Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	1165000	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	793000	shares
CY2021Q3	us-gaap	Treasury Stock Value TreasuryStockValue	7518000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	4843000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	136603000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	156371000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	172330000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	203788000	USD
CY2021Q3	lxrx	Netproductrevenue Netproductrevenue	0	USD
CY2020Q3	lxrx	Netproductrevenue Netproductrevenue	6542000	USD
	lxrx	Netproductrevenue Netproductrevenue	0	USD
	lxrx	Netproductrevenue Netproductrevenue	23404000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33000	USD
CY2021Q3	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	23000	USD
CY2020Q3	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	92000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	284000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	359000	USD
CY2021Q3	us-gaap	Revenues Revenues	23000	USD
CY2020Q3	us-gaap	Revenues Revenues	6634000	USD
	us-gaap	Revenues Revenues	284000	USD
	us-gaap	Revenues Revenues	23796000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	633000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1929000	USD
CY2021Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1138000	USD
CY2020Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1029000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3608000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	5154000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15682000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40147000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38548000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	152629000	USD
CY2021Q3	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1574000	USD
CY2020Q3	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	875000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	4741000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	5440000	USD
CY2021Q3	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	7303000	USD
CY2020Q3	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	11997000	USD
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	23496000	USD
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	40798000	USD
CY2021Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1600000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	22985000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	52777000	USD
	us-gaap	Operating Expenses OperatingExpenses	62044000	USD
	us-gaap	Operating Expenses OperatingExpenses	196956000	USD
CY2021Q3	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	0	USD
CY2020Q3	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	132818000	USD
	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	0	USD
	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	132818000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22962000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	86675000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-61760000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40342000	USD
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-255000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-255000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	171000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	4118000	USD
	us-gaap	Interest Expense InterestExpense	507000	USD
	us-gaap	Interest Expense InterestExpense	14374000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	301000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	120000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1892000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-23122000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	82603000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-62147000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-53079000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145820000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107309000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144558000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106974000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145820000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117552000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	144558000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106974000	shares
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-277000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-49000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23122000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	82326000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62146000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-53128000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	117101000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4432000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2000	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	923000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	776000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54777000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4258000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	103000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-548000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10687000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1904000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14096000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-277000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	87639000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	156371000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2851000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	548000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16399000	USD
CY2021Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2675000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-20958000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	152547000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2786000	USD
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	88000	shares
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	31000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-18067000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	137233000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2712000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	658000	USD
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4177000	shares
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19123000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-23122000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	136603000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-62147000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-53079000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	180000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2590000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8349000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10594000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	46000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	995000	USD
	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	0	USD
	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	132818000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1600000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-255000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-372000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-52201000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-345000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1985000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6008000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-459000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-314000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-13433000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14281000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64189000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-108730000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1198000	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33000	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	160385000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	28880000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	53197000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	26092000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	229500000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3986000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	336655000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	36705000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2675000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1026000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	210760000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34030000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-211786000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-34145000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	16139000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126263000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36112000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92118000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52251000	USD
	us-gaap	Interest Paid Net InterestPaidNet	307000	USD
	us-gaap	Interest Paid Net InterestPaidNet	16892000	USD
CY2021Q3	lxrx	Initial Recognition Of Right Of Use Asset InitialRecognitionOfRightOfUseAsset	1704000	USD
CY2020Q4	lxrx	Initial Recognition Of Right Of Use Asset InitialRecognitionOfRightOfUseAsset	0	USD
CY2020Q3	lxrx	Liabilities Assumed By Ter Sera LiabilitiesAssumedByTerSera	3180000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14096000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span>
CY2021Q3	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	7544000	USD
CY2020Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	21962000	USD
CY2021Q3	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	4172000	USD
CY2020Q4	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	6200000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1027000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	553000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1465000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	976000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	14208000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	29691000	USD
CY2021Q1	lxrx	Lexicon Incremental Borrowing Rate LexiconIncrementalBorrowingRate	9
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	281000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.31
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	295000	USD
	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	1.1	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	1200000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1600000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	92118000	USD
CY2021Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	28800000	USD
CY2021Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	120918000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	126263000	USD
CY2020Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	26012000	USD
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	152275000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6160000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6110000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4849000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5815000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1311000	USD
CY2021Q1	lxrx	Share Price In January2021 Atm Offering SharePriceInJanuary2021ATMOffering	8.463	shares
CY2021Q1	lxrx	Proceeds From January2021 Atm Offering ProceedsFromJanuary2021ATMOffering	16400000	USD
CY2021Q3	lxrx	Shares Sold In September2021 Atm Offerring SharesSoldInSeptember2021ATMOfferring	4176953	shares
CY2021Q3	lxrx	Share Price In September2021 Atm Offerring SharePriceInSeptember2021ATMOfferring	4.732	USD
CY2021Q3	lxrx	Proceeds From September2021 Atm Offering ProceedsFromSeptember2021ATMOffering	19.1	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	386000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2508000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1027000	USD
CY2021Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1481000	USD
CY2020Q3	lxrx	Lxrx Sanofiterminationcashpayment Lxrx_Sanofiterminationcashpayment	26000000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	300000	USD
CY2019Q3	lxrx	Settlement Payment From Termination SettlementPaymentFromTermination	208000000	USD
CY2020Q1	lxrx	Lxrx Sanofi Initial Cash Payment Lxrx_sanofiInitialCashPayment	26000000	USD
CY2020Q3	lxrx	Lxrx Sanofi Initial Cash Payment Lxrx_sanofiInitialCashPayment	26000000	USD
	lxrx	Atm Offering Total ATMOfferingTotal	50000000	USD
CY2020	lxrx	Shares Sold In Nov2020 Atm Offering SharesSoldInNov2020ATMOffering	3709233	shares
CY2020	lxrx	Share Price In November20 Atm Offering SharePriceInNovember20ATMOffering	1.992	USD
CY2020	lxrx	Proceeds From Nov2020 Atm Offering ProceedsFromNov2020ATMOffering	7000000	USD
CY2021Q1	lxrx	Shares Sold In January2021 Atm Offering SharesSoldInJanuary2021ATMOffering	2000000	shares
CY2020Q3	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	160400000	USD
CY2020Q3	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	132800000	USD
	lxrx	Xermelo Pretax Net Loss XermeloPretaxNetLoss	-12100000	USD
	lxrx	Ter Sera Maximum Development Regulatory And Commercial Milestones TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones	65000000	USD
CY2020Q3	lxrx	Xermelo Pretax Net Loss XermeloPretaxNetLoss	-2100000	USD
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	USD
CY2014Q4	lxrx	Conv Debt Instrument Interest Rate Stated Percentage ConvDebtInstrumentInterestRateStatedPercentage	0.0525
CY2020Q3	lxrx	Convertible Debt Exchange Total Principal Amount ConvertibleDebtExchangeTotalPrincipalAmount	75800000	USD
CY2021Q3	lxrx	Convertible Debt Exchange Remaining Notes ConvertibleDebtExchangeRemainingNotes	11700000	USD
CY2014Q4	lxrx	Conv Debt Instrument Interest Rate Stated Percentage ConvDebtInstrumentInterestRateStatedPercentage	0.0525
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	118.4553
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.442
CY2021Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	11900000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2500000	USD
CY2021Q3	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	1000000	USD
CY2021Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1500000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	286000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1163000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	531000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	544000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	370000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2894000	USD
	us-gaap	Severance Costs1 SeveranceCosts1	5500000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-23122000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	82603000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-62147000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-53079000	USD
CY2021Q3	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2020Q3	us-gaap	Dilutive Securities DilutiveSecurities	1258000	USD
	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2021Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-23122000	USD
CY2020Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	83861000	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-62147000	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-53079000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145820000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107309000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144558000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106974000	shares
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	51000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	10192000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145820000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117552000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	144558000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106974000	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10615	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11773	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10615	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11859	shares

Files In Submission

Name	View Source	Status
0001062822-21-000063-index-headers.html	Edgar Link	pending
0001062822-21-000063-index.html	Edgar Link	pending
0001062822-21-000063.txt	Edgar Link	pending
0001062822-21-000063-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20210930.htm	Edgar Link	pending
lxrx-20210930.xsd	Edgar Link	pending
lxrx-20210930_cal.xml	Edgar Link	unprocessable
lxrx-20210930_def.xml	Edgar Link	unprocessable
lxrx-20210930_htm.xml	Edgar Link	completed
lxrx-20210930_lab.xml	Edgar Link	unprocessable
lxrx-20210930_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2021 Q4 Form 10-Q Financial Statement

#000106282221000063 Filed on November 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2021 Q4 Form 10-Q Financial Statement

#000106282221000063 Filed on November 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx